Skip to main content

Advertisement

Table 1 Patient characteristics at baseline

From: A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

Variable n
Patients 35
Median age years (range) 64 (40–75)
Menopause  
 Pre 9
 Post 26
ECOG PS  
 0 28
 1 7
Hormone receptor  
 Positive 28
 Negative 7
Stage  
 Inoperable 14
 Recurrent 21
Neoadjuvant/adjuvant chemotherapy  
 Yes 15
 No 20
Prior anthracycline 10
Prior taxanes 9
No. of metastatic sites  
 1 17
 2 12
 3 5
 4 1
Metastatic site  
 Lung 17
 Bone 12
 Liver 7
 Lymph node 12
 Pleura 3
 Skin 2
 Adrenal 1
Treatment exposure, cycles (range) 8 (1–21)
Dose reduction  
 Yes 4
 No 31
Schedule modification  
 Yes 19
 No 16
  1. ECOG PS, Eastern Cooperative Oncology Group performance status